$4.80
+0.58 (+13.74%)
Open$4.29
Previous Close$4.22
Day High$4.92
Day Low$4.13
52W High$5.30
52W Low$2.69
Volume—
Avg Volume126.9K
Market Cap207.72M
P/E Ratio49.45
EPS$0.07
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
-16.0% upside
Current
$4.80
$4.80
Target
$4.03
$4.03
$3.03
$4.03 avg
$5.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.71M | 21.78M | 21.76M |
| Net Income | 4.38M | 3.81M | 4.44M |
| Profit Margin | 20.2% | 17.5% | 20.4% |
| EBITDA | 6.15M | 6.17M | 6.37M |
| Free Cash Flow | 3.82M | 4.48M | 4.63M |
| Rev Growth | +1.1% | -8.2% | +18.1% |
| Debt/Equity | 0.50 | 0.50 | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |